Tolerance and Activity Assessment of High Doses of Favipiravir in Male Survivors With Ebola Virus in the Semen

Trial Profile

Tolerance and Activity Assessment of High Doses of Favipiravir in Male Survivors With Ebola Virus in the Semen

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 May 2016

At a glance

  • Drugs Favipiravir (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Acronyms FORCE
  • Most Recent Events

    • 03 May 2016 Status changed from not yet recruiting to recruiting.
    • 18 Apr 2016 New trial record
    • 15 Apr 2016 Time frame of primary end point is been changed from 21 days to 14 days.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top